Related Experiment Video
Updated: Mar 20, 2026
05:25
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
1.4K
Adjunctive therapies for Kawasaki disease
Anita J Campbell1, Jane C Burns2
1Infectious Diseases Department, Princess Margaret Hospital, Roberts Road, Subiaco 6008, Perth, WA, Australia.
The Journal of Infection
|June 1, 2016
Summary
Kawasaki disease (KD) can lead to coronary artery aneurysms (CAA), especially in non-responders to IVIG treatment. Identifying high-risk patients is crucial for selecting effective adjunctive therapies to prevent CAA progression.
Area of Science:
- Pediatric Cardiology
- Immunology
Background:
- Kawasaki disease (KD) is a leading cause of acquired pediatric heart disease.
- Preventing coronary artery aneurysms (CAA) is the primary treatment goal in KD.
- A significant subset of KD patients exhibit resistance to initial intravenous immunoglobulin (IVIG) therapy, increasing CAA risk.
Purpose of the Study:
- To explore the mechanisms of IVIG resistance in Kawasaki disease.
- To identify high-risk patient populations for coronary artery aneurysm (CAA) development.
- To guide the selection of adjunctive therapies for refractory KD and early CAA.
Main Methods:
- Review of existing literature on KD treatment and IVIG resistance.
- Analysis of risk factors and early indicators for CAA development in KD patients.
- Exploration of potential adjunctive therapies based on proposed mechanisms of action.
Main Results:
- 10-20% of KD patients are resistant to IVIG, facing a nine-fold higher CAA risk.
- 80-90% of patients who develop CAA show early abnormal coronary artery dimensions.
- Potential adjunctive therapies include glucocorticoids, TNF inhibitors, calcineurin inhibitors, IL-1 blockers, and statins.
Conclusions:
- Understanding IVIG's mechanism is key to addressing resistance and guiding therapy.
- Early identification of high-risk KD patients via echocardiography is vital.
- Laboratory data may inform the choice of adjunctive treatments due to trial limitations.
Keywords:
Adjunctive therapiesAnakinraAtorvastatinCyclosporinGlucocorticoidsInfliximabIntravenous immunoglobulin resistanceRefractory Kawasaki diseaseMore Related Videos
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
531
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
531
01:21Rheumatic Heart Disease III: Medical Management
480
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
480
01:14Myocarditis III: Medical Management
310
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
310
01:20Rheumatic Heart Disease IV: Nursing Management
428
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
428
01:26Mitral Stenosis III: Medical Management
423
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
423
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
591
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
591